ACRO releases Principles for Responsible AI in clinical research
Wed 20 Dec 2023
The Association of Clinical Research Organizations (ACRO), representing clinical research organisations (CROs) and clinical technology companies, has announced the release of its Principles for Responsible AI.
These principles are aimed at guiding the development and deployment of AI tools in drug development, emphasising thoughtful design, transparency, and accountability.
The principles were formulated by a team of CRO and technology subject matter experts. They are intended to guide the use of AI in drug development, ensuring that these advanced tools are used responsibly and ethically, particularly in the context of clinical research.
Stephen Pyke, Chief Clinical Data & Digital Officer for Parexel and Chair of the ACRO AI/ML Committee, said: “Just as ChatGPT has ushered in a new era for AI, ACRO member companies recognise its enormous potential to improve the design, conduct and analysis of clinical trials.”
Pyke acknowledged the potential risks associated with AI tools and highlighted the commitment to a responsible approach that prioritises patient needs and expectations.
ACRO’s Principles for Responsible AI are informed by frameworks developed by the National Institute of Standards and Technologies (NIST) and other authoritative bodies.
They include 10 recommendations for organisations to consider as they develop and use AI technologies, tailored to the specific context of drug development. These principles also provide additional guidelines and references relevant to this field.
Pyke added: “ACRO looks forward to working with regulators and policy makers around the world, so that our industry can benefit from the promise of AI while embracing a commitment to responsible development and use of these new technologies.”
These principles reflect ACRO’s stance in addressing the rapid advancement of AI in clinical research, ensuring that its integration into drug development is both effective and ethically sound.